Growth Metrics

BioNTech SE (BNTX) Debt to Equity (2018 - 2021)

BioNTech SE (BNTX) posted Debt to Equity of $0.12 for Q4 2021, down 34.28% on a QoQ basis from $0.18 in Q4 2020, and down 34.28% year-over-year from $0.18 in Q4 2020.

BioNTech SE (BNTX) has 4 years of Debt to Equity data on file, last reported at $0.12 in Q4 2021.

  • In Q4 2021, Debt to Equity fell 34.28% year-over-year to $0.12; the TTM figure through Dec 2021 stood at $0.12 (down 34.28% YoY), while the FY2021 annual figure was $0.12, down 34.28% from the prior year.
  • Debt to Equity retreated to $0.12 in Q4 2021, from $0.18 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.23 in Q4 2018 and bottomed at $0.12 in Q4 2021.
  • A 4-year average of $0.17 and a median of $0.17 in 2020 frame the typical range for Debt to Equity.
  • Annual changes were most pronounced in 2020 — Debt to Equity rose 8.98% — and 2021, when it tumbled 34.28%.
  • Year by year, Debt to Equity stood at $0.23 in 2018, then tumbled by 31.37% to $0.16 in 2019, then climbed by 8.98% to $0.18 in 2020, then tumbled by 34.28% to $0.12 in 2021.
  • The last three Debt to Equity figures came in at $0.12 (Q4 2021), $0.18 (Q4 2020), and $0.16 (Q4 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.06
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 BioNTech SE 27.66 Bn 7.53 Bn 668.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 0.12
Dec 31, 2020 0.18
Dec 31, 2019 0.16
Dec 31, 2018 0.23